E2A suppresses invasion and migration by targeting YAP in colorectal cancer cells

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Zhao, Hongchao ^a,b   Huang, Ao ^a,b   Li, Pu ^a   Quan, Yingjun ^a,b   Feng, Bo ^a,b   Chen, Xuehua ^a   Mao, Zhihai ^a,b   Zhu, Zhenggang ^a   Zheng, Minhua ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Minimally Invasive Surgery Center   (China)

Author keywords

Colorectal cancer; E2A; EMT; Metastasis; YAP

Indexed keywords

MESSENGER RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E12; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR E47; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; E2A GENE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MIDDLE AGED; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; YAP GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BASE SEQUENCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; COLORECTAL NEOPLASMS; DNA PRIMERS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84890911521     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-317     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458. 10.1038/nrc1098, 12778135.
3. Nadal C, Maurel J, Gascon P. Is there a genetic signature for liver metastasis in colorectal cancer?. World J Gastroenterol 2007, 13:5832-5844.
4. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989, 56:777-783. 10.1016/0092-8674(89)90682-X, 2493990.
5. Chakraborty T, Brennan TJ, Li L, Edmondson D, Olson EN. Inefficient homooligomerization contributes to the dependence of myogenin on E2A products for efficient DNA binding. Mol Cell Biol 1991, 11:3633-3641. 361113, 1646392.
6. Lassar AB, Buskin JN, Lockshon D, Davis RL, Apone S, Hauschka SD, Weintraub H. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell 1989, 58:823-831. 10.1016/0092-8674(89)90935-5, 2550138.
7. Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, Cabrera CV, Buskin JN, Hauschka SD, Lassar AB, et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 1989, 58:537-544. 10.1016/0092-8674(89)90434-0, 2503252.
8. Aronheim A, Shiran R, Rosen A, Walker MD. Cell-specific expression of helix-loop-helix transcription factors encoded by the E2A gene. Nucleic Acids Res 1993, 21:1601-1606. 10.1093/nar/21.7.1601, 309369, 8479911.
9. Watada H, Kajimoto Y, Umayahara Y, Matsuoka T, Morishima T, Yamasaki Y, Kawamori R, Kamada T. Ubiquitous, but variable, expression of two alternatively spliced mRNAs encoding mouse homologues of transcription factors E47 and E12. Gene 1995, 153:255-259. 10.1016/0378-1119(94)00765-K, 7875598.
10. Zhuang Y, Soriano P, Weintraub H. The helix-loop-helix gene E2A is required for B cell formation. Cell 1994, 79:875-884. 10.1016/0092-8674(94)90076-0, 8001124.
11. LeBrun DP. E2A basic helix-loop-helix transcription factors in human leukemia. Front Biosci 2003, 8:s206-s222. 10.2741/1030, 12700034.
12. Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, Krop I, Schlissel MS, Feeney AJ, van Roon M, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994, 79:885-892. 10.1016/0092-8674(94)90077-9, 8001125.
13. Engel I, Murre C. Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas. Proc Natl Acad Sci USA 1999, 96:996-1001. 10.1073/pnas.96.3.996, 15339, 9927682.
14. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA, Cano A. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 2001, 276:27424-27431. 10.1074/jbc.M100827200, 11309385.
15. Wilson JW, Deed RW, Inoue T, Balzi M, Becciolini A, Faraoni P, Potten CS, Norton JD. Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res 2001, 61:8803-8810.
16. Li P, Lin Y, Zhang Y, Zhu Z, Huo K. SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma. J Transl Med 2013, 11:52. 10.1186/1479-5876-11-52, 3599991, 23452395.
17. Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, et al. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 2013, 8:e66782. 10.1371/journal.pone.0066782, 3691322, 23826132.
18. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273. 10.1038/nrc2620, 19262571.
19. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829. 10.1016/j.devcel.2008.05.009, 18539112.
20. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
21. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009, 361:2449-2460. 10.1056/NEJMra0804588, 2843693, 20018966.
22. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695. 10.1016/j.cell.2006.11.001, 17110329.
23. Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY, Lee WH. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011, 30:2463-2474. 10.1038/onc.2010.618, 21258409.
24. Hata F, Nishimori H, Yasoshima T, Tanaka H, Ohno K, Yanai Y, Ezoe E, Kamiguchi K, Isomura H, Denno R, et al. Profiling analysis of differential gene expression between hematogenous and peritoneal metastatic sublines of human pancreatic cancer using a DNA chip. J Exp Clin Cancer Res 2004, 23:513-520.
25. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
26. Oh SJ, Shin JH, Kim TH, Lee HS, Yoo JY, Ahn JY, Broaddus RR, Taketo MM, Lydon JP, Leach RE, et al. beta-catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J Pathol 2013, 231:210-222. 10.1002/path.4224, 23784889.
27. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006, 103:12405-12410. 10.1073/pnas.0605579103, 1533802, 16894141.
28. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267. 10.1016/j.cell.2006.05.030, 3026384, 16814713.
29. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133. 10.1016/j.cell.2007.07.019, 2666353, 17889654.
30. Pan D. Hippo signaling in organ size control. Genes Dev 2007, 21:886-897. 10.1101/gad.1536007, 17437995.
31. Edgar BA. From cell structure to transcription: hippo forges a new path. Cell 2006, 124:267-273. 10.1016/j.cell.2006.01.005, 16439203.
32. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010, 19:491-505. 10.1016/j.devcel.2010.09.011, 3124840, 20951342.
33. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008, 22:1962-1971. 10.1101/gad.1664408, 2492741, 18579750.
34. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008, 39:1582-1589. 10.1016/j.humpath.2008.04.012, 2720436, 18703216.
35. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007, 17:2054-2060. 10.1016/j.cub.2007.10.039, 17980593.
36. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 2013, 8:e65539. 10.1371/journal.pone.0065539, 3677905, 23762387.
37. Konsavage WM, Kyler SL, Rennoll SA, Jin G, Yochum GS. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem 2012, 287:11730-11739. 10.1074/jbc.M111.327767, 3320921, 22337891.